Merck & Co. is making waves as an undervalued S&P 500 stock, boasting a forward P/E ratio of 10.52 and strong hedge fund ...

“Due to significant reductions in demand for these products, the company has decided to cease operations at the plant,” the ...

The general mood among these heavyweight investors is divided, with 63% leaning bullish and 36% bearish. Among these notable ...

A new precision oncology paper was published in Oncotarget, Volume 16, on March 12, 2025, titled “Worldwide Innovative ...

Promising results from an early-stage trial suggest that lenacapavir injections might offer long-lasting protection.

Keros Therapeutics' stock has plummeted over 70% due to safety issues in its phase 2 PAH study, halting all trial arms. Learn more about KROS stock here.

The Breez 2 mL micro-bioreactor platform is a fully automated, functionally closed, and continuous perfusion cell culture ...

Germany's financial markets watchdog is looking at whether Bayer fairly disclosed plans for shareholder approval of a capital ...

Two years after first announcing the partnership, Boehringer Ingelheim and software firm Veeva Systems have launched ...

According to the company, the new, 225,000-square-foot expansion is a "crucial component" of a more than $12 billion infusion ...

The drugmaker Merck announced it has opened a $1 billion vaccine manufacturing facility in north Durham, a ...